Biomea Fusion : BMEA Corporate Presentation - January 2022

Corporate Presentation

January 2022

Disclaimer and Forward-Looking Statement

Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future business and financial performance of Biomea Fusion, Inc. (the "Company") and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. All statements other than statements of historical fact could be deemed forward-looking, including any projections of financial information or profitability, the initiation, timing and results of pending or future preclinical studies and clinical trials, the actual or potential actions of the FDA, the status and timing of ongoing research, development and corporate partnering activities, any statements about historical results that may suggest trends for the Company's business; any statements of the plans, strategies, and objectives of management for future operations; any statements of expectation or belief regarding future events, potential markets or market size, or technology developments, and other factors affecting the Company's financial condition or operations. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this presentation are made only as of the date hereof. Except as required by law, the Company assumes no obligation and does not intend to update these forward-looking statements or to conform these statements to actual results or to changes in the Company's expectations. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

2

Experienced and Successful Management Team

Novel FUSION™ Platform

BMF-219 - Clinical Stage

Oncology Asset

Multiple Oncology Programs built from FUSIONTM Platform

We Aim To Cure

Biomea Fusion is a clinical-stage biopharmaceutical company focused on the discovery and development of irreversible small-molecule drugs to treat patients with genetically defined cancers. We believe that our approach may lead to significant improvement and extension of life for patients. Our team is engaged in all phases of drug discovery and development, including target selection, small molecule design, and preclinical and clinical studies to develop innovative medicines.

3

BMF-219 - Novel Irreversible Covalent Inhibitor of Menin

Pipeline-in-a-Pill - Single Agent for Multiple Indications

Strong Pathway Control

Large effect on target genes and proteins leading to cell death

Multiple Shots on Goal

Acute leukemias, MYC addicted and driven cancers, RAS/RAF driven solid tumors

Consistent On-Target Effect

Pathway control and cell killing seen at same predicted dose across indications

Wide Safety Margin

Strong preclinical safety profile from animal studies

4

Our Team - 10+ Years of Success Together

Thomas Butler Ramses Erdtmann	Franco Valle	Naomi Cretcher	Heow Tan	Steve Morris MD	Thorsten Kirschberg	Jim Palmer
Chairman & CEO	President & COO	Chief Financial	Chief of People	Chief Technical & Chief Medical Officer	EVP of Chemistry	VP of Drug
		Officer		Quality Officer	Consultant		Discovery
15+ years in Life Science	15+ years in Life Science	15+ years in Life Science	15+ years in Life Science	22+ years in Life Science	25+ years in Life Science	25+ years in Life Science	30+ years in Life Science
Pharmacyclics	Pharmacyclics	Eidos Therapeutics	Pharmacyclics	Pharmacyclics	HealthChart LLC	Terns Pharmaceuticals	Biota Ltd
Gilead Sciences	Oxygen Investments	Iovance Biotherapeutics	Genentech	Collegium Pharmaceutical	Insight Genetics	Gilead Sciences	Cytopia Ltd.
UCLA - MBA Finance	Commerzbank	Pharmacyclics	UC Irvine, BA Comm	Praecis Pharmaceuticals	St. Jude Children's	Cell Gate	Rigel, Inc.
UCSB, MS - Chemistry	University of Münster,	CallidusCloud	SF State University, Comm	Ohio State University	Research Hospital	Golden Gate University,	Celera Genomics
	Master's in Banking &	PricewaterhouseCoopers		Santa Clara University	Board certified internist	MBA	Prototek Inc.
	Corp Finance	San Jose State University, BS	Leavey School of Business,	(Univ. of Texas SW HSC)	University of Münster,	Purdue University
		Corporate Finance		MBA - Finance & Mgmt	and medical oncologist	Ph.D., Chemistry	Ph.D. Organic Chemistry
					(Yale University School of
					Medicine)

5